Allergan "paid kickbacks to induce physicals to inject Botox for off-label uses and Allergan also taught doctors how to bill for off-label uses, including coaching doctors how to miscode Botox claims leading to millions of dollars of false claims being to submitted to federal and state programs", Assistant Attorney-General Tony West said. "The FDA had approved therapeutic uses of Botox for only four rare conditions, yet Allergan made it a top corporate priority to maximise sales of far more lucrative off-label uses that were not approved by the FDA," said Sally Yates, US Attorney for the Northern District of Georgia. "Allergan further demanded tremendous growth in these off-label sales year after year, even when there was little clinical evidence that these uses were effective." The investigation was sparked by a whistleblower complaint, officials said, and five whistleblowers will split $US37.8 million of the government's share of the settlement.